Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
anthracycline
cancer
cardioprotection
cardiotoxicity
chemotherapy
doxorubicin
Journal
Clinical and experimental pharmacology & physiology
ISSN: 1440-1681
Titre abrégé: Clin Exp Pharmacol Physiol
Pays: Australia
ID NLM: 0425076
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
12
06
2018
revised:
31
08
2018
accepted:
13
09
2018
pubmed:
24
9
2018
medline:
21
4
2020
entrez:
24
9
2018
Statut:
ppublish
Résumé
Anthracycline chemotherapy has a prominent role in treating many forms of cancer. Unfortunately, cardiotoxic side effects represent a serious limitation to their use, with doxorubicin being the leading drug of the group. Indeed, anthracycline-induced cardiomyopathy is an important public health concern because it may not be detected for many years and remains a lifelong threat. Even after decades of investigation, neither the exact mode of action of anthracyclines nor the pathways leading to their side effect are fully understood. It is increasingly important to establish collaboration between oncologists and cardiologists to improve the management of cancer patient receiving anthracyclines. This article reviews the clinical course, pathogenesis, cardiac monitoring and new concepts in diagnosing and preventing anthracycline-induced cardiotoxicity.
Identifiants
pubmed: 30244497
doi: 10.1111/1440-1681.13036
doi:
Substances chimiques
Anthracyclines
0
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
204-215Informations de copyright
© 2018 John Wiley & Sons Australia, Ltd.